An international expert panel of 45 members established consensus recommendations on corticosteroid management during clinical trials for inflammatory bowel disease at the United European Gastroenterology (UEG) Week 2025. They identified that inconsistent tapering and prolonged exposure compromise trial validity and increase risks. Utilizing a structured Delphi process, the panel emphasized the need for harmonized tapering schedules and strict definitions for steroid-related endpoints. While they highlighted favored regimens and operational details, consensus on corticosteroid withdrawal duration to define remission was not achieved, aiming to enhance trial reliability.

Source: United European Gastroenterology (UEG) Week 2025